Fill in some text

What Changed on March 20?

Semaglutide’s patent expired in India, allowing 40+ companies to enter the market almost overnight.

From ₹16,400 to ₹1,290

In just three weeks, the monthly cost of semaglutide crashed by 92%, making the drug far more accessible.

What Is Semaglutide?

It is a GLP-1 drug that helps control appetite, reduce blood sugar, and support weight loss.

The Price War Has Begun

Indian pharma players like Natco, Eris, Glenmark, Alkem, Zydus, Sun Pharma, and Dr. Reddy’s have joined the race.

Where Is the Real Opportunity?

Beyond pharma, diagnostics, medical devices, and digital health platforms could benefit from rising demand.

This Trend Goes Beyond Pharma

As GLP-1 adoption rises, spending patterns may shift toward health food, fitness, and preventive healthcare.

Read Now

Discover the full market impact, key stock opportunities, and what this trend could mean for your portfolio.